J&J's tapentadol ER tablets get FDA complete response letter
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has received a complete response letter from the US FDA for its NDA for tapentadol extended-release tablets. The application seeks approval to market the drug as an oral analgesic for the management of moderate to severe chronic pain in patients aged 18 years or older.